Andrew D. Seidman, MD

Articles by Andrew D. Seidman, MD

Future Directions in Care for HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Novel Treatment Strategies for HER2-Low Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 8th 2022

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.

Establishing the Paradigm of HER2-Low Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 8th 2022

Expert perspectives on the advent of HER2-low disease and how it has been historically managed since its emergence as a subset of breast cancer.

Ongoing Studies With Novel Agents in HER2+ Metastatic Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 1st 2022

Before sharing a final review of treatment options for HER2+ metastatic breast cancer, expert oncologists highlight ongoing clinical trials in this setting.

HER2+ mBC: Practical Selection and Sequencing of Therapy

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

August 1st 2022

Comprehensive discussion on how oncologists may practically select and sequence novel treatment approaches in HER2+ metastatic breast cancer.

Novel Treatment Approaches to Brain Metastases in HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 25th 2022

Focusing on the management of brain metastases in HER2+ metastatic breast cancer, panelists share trial data on tucatinib and trastuzumab deruxtecan.

HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Early-Stage HER2+ Breast Cancer: Novel Perioperative Treatment Strategies

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 11th 2022

Subject matter experts in breast oncology discuss ongoing clinical trials in early-stage HER2+ breast cancer that focus on perioperative therapies.

Establishing the Role of Neratinib Therapy in Early-Stage HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 11th 2022

Expert oncologists share their perspectives on when it would be appropriate to consider neratinib therapy in early-stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Optimizing Use of T-DM1

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,William J. Gradishar, MD,Tiffany A. Traina, MD,Stephanie L. Graff, MD, FACP

July 4th 2022

A brief discussion on the role of trastuzumab emtansine, T-DM1, in patients with early-stage HER2+ breast cancer.

Subcutaneous HP Therapy in Early-Stage HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

July 4th 2022

Panelists review clinical data behind subcutaneous HP therapy in early stage HER2+ breast cancer and elucidate the real-world use of this approach.

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Hospitalists and Nonphysician Providers Can Step Into the Breach

ByAndrew D. Seidman, MD

March 14th 2018

Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.

Dr. Seidman on Ixabepilone in Patients With Aggressive Breast Cancer

ByAndrew D. Seidman, MD

March 18th 2016

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Dr. Seidman Discusses Less Lymph Node Surgery

ByAndrew D. Seidman, MD

July 11th 2013

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Dr. Seidman on Personalized and Precision Medicine

ByAndrew D. Seidman, MD

June 28th 2013

Andrew D. Seidman, MD, from the Memorial Sloan-Kettering Cancer Center, describes his excitement over the genetic advances made in the treatment of patients with cancer.